Skip to main content

Table 1 Immunotherapy (αPD1 and αCTLA4) response probability based on logistic regression models of tumor mutational burden (TMB), neoepitope burden (Neoepitopes), and combined tumor DNA- and RNA- variant burden (TVB) for melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). P values are reported on a per-model basis without correction for multiple comparisons per cancer type

From: Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival

Cancer type & Metric aPD1 aCTLA4 p-value
N Response Probability (25th %ile) Response Probability (75th %ile) N Response Probability (25th %ile) Response Probability (75th %ile)
Melanoma
 TMB 50 0.456 0.507 195 0.298 0.342 0.267
 Neoepitopes 50 0.470 0.507 195 0.302 0.334 0.378
 TVB 27 0.367 0.490 61 0.307 0.424 0.079
NSCLC
 TMB 33 0.291 0.578     0.034
 Neoepitopes 33 0.345 0.583     0.053
RCC
 TMB 50 0.656 0.666     0.894
 Neoepitopes 50 0.662 0.66     0.973
 TVB 17 0.641 0.538     0.600